Details About Generic Salt ::  Inflixim

Main Medicine Class:: Monoclonal antibody   

(in-FLICK-sih-mab)

Remicade

Powder for Injection: 100 mg

Class: Monoclonal antibody

 

Drugs Class ::

 Action Neutralizes the biological activity of TNF by binding to its soluble and transmembrane forms and inhibits TNF receptor binding.

Indications for Drugs ::

 Indications Reduce signs and symptoms and induce and maintain clinical remission of moderate to severe Crohn disease; reduce number of draining enterocutaneous fistulas in Crohn disease; in combination with methotrexate to reduce signs and symptoms, inhibit progression of structural damage, and improve physical function of rheumatoid arthritis in patients with inadequate response to methotrexate.

Drug Dose ::

 Route/Dosage

Rheumatoid Arthritis

ADULTS: IV 3 mg/kg infusion followed by additional 3 mg/kg doses at 2 and 6 wk after the first infusion, then q 8 wk thereafter.

Moderate to Severe Crohn Disease

ADULTS: IV 5 mg/kg as an induction regimen at 0.2 and 6 wk, followed by a maintenance regimen of 5 mg/kg q 8 wk. In patients who respond and then lose their response, consider treatment with 10 mg/kg.

Fistulizing Crohn Disease

ADULTS: IV 5 mg/kg initially followed by 5 mg/kg doses 2 and 6 wk after the first infusion.

Contraindication ::

 Contraindications Hypersensitivity to murine proteins or other components of product; moderate or severe CHF.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Use with caution because of higher incidence of infection in the elderly. Autoimmunity: May result in autoantibody formation and, rarely, development of a lupus-like syndrome. CHF: Preliminary results of ongoing trials of patients with moderate to severe CHF have reported higher incidences of hospitalization and mortality for worsening heart failure in patients receiving infliximab. Infection: Serious infections including tuberculosis (frequently disseminated or extrapulmonary), invasive fungal infections, sepsis, and other opportunistic infections may occur. Neurologic events: Rarely, optic neuritis, seizure and new onset or exacerbation of clinical symptoms or radiographic evidence of CNS demyelinating disorders, including multiple sclerosis, may occur.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Hypertension; hypotension; syncope; palpitation; tachycardia; cardiac failure; myocardial ischemia; brain infarction; pulmonary embolism; deep thrombophlebitis; chest pain. CNS: Headache; dizziness; upper motor neuron lesion; anxiety; confusion; delirium; depression; somnolence; suicide attempt. DERM: Urticaria; rash; furunculosis; sweating. EENT: Pharyngitis; ceruminosis. GI: Nausea; abdominal pain; vomiting; diarrhea; gastric ulcer; intestinal obstruction, perforation, and stenosis; pancreatitis; proctalgia. GU: UTI; azotemia; dysuria; hydronephrosis; kidney infection; renal failure; ureteral obstruction. HEMA: Splenic infarction; splenomegaly; lymphoma; thrombocytopenia; anemia; leukopenia; lymphadenopathy. HEPA: Elevated ALT and AST. META: Dehydration; pancreatic insufficiency; weight loss. RESP: Dyspnea; upper respiratory tract infection; coughing; sinusitis; rhinitis; adult respiratory distress syndrome; bronchitis; pleurisy; pneumonia; pulmonary infiltration; respiratory insufficiency. OTHER: Infusion reactions; infections; lupus-like syndrome; fatigue; fever; back pain; pain; pruritus; moniliasis; arthropathy; bone fracture; myalgia; tendon disorder and injury; abdominal hernia; falling; rheumatoid nodules; abscess; cellulitis; fever; sepsis; cholecystitis.

Drug Mode of Action ::  

 Action Neutralizes the biological activity of TNF by binding to its soluble and transmembrane forms and inhibits TNF receptor binding.

Drug Interactions ::

 Interactions

Vaccines: Do not administer live vaccines concurrently. Incompatibilities: Do not infuse concomitantly with other agents in the same IV line.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note history of allergic reactions to rats or mice.
• Assess patient for evidence of active infection. Report to health care provider if noted.
• Monitor patient for hypersensitivity reactions during and shortly after infusion.

Drug Storage/Management ::

 Administration/Storage

• Reconstitute powder using 10 mL of sterile water only. Gently swirl solution to dissolve. Do not shake vial. Allow reconstituted solution to sit for 5 min. Solution should be colorless to light yellow and opalescent.
• Do not use if reconstituted solution is discolored or contains opaque particles.
• Prepare infusion solution by further diluting to a total volume of 250 mL with 0.9% Sodium Chloride Injection. Gently mix diluted solution.
• Use diluted solution within 3 hr of preparation.
• Administer via IV route only. Infuse slowly over a period of not less than 2 hr.
• Use in-line, sterile, low-protein filter of up to 1.2 mcm pore size.
• Do not infuse concomitantly in the same IV line with any other agents.
• Do not reuse or store any unused portion of the infusion solution.
• Store powder for injection in refrigerator. Do not freeze.
• Do not use beyond expiration date.

Drug Notes ::

 Patient/Family Education

• Explain name, dose, action, and potential side effects of drug.
• Advise patient to notify health care provider immediately if any of the following occur: rash; hives; shortness of breath; swelling of the eyes, mouth, or throat.
• Advise patient to notify the health care provider if any of the following are noted: new or worsening joint or muscle pain; fever or other signs of infection; sore throat; difficulty swallowing; swelling of hands or face; headache.
• Advise women of child-bearing potential to inform health care provider if becoming pregnant or breastfeeding.
• Warn patient not to receive live vaccines while taking this drug.
• Instruct patient not to take any prescription or OTC medications or dietary supplements unless advised by health care provider.
• Advise patient that follow-up visits for examinations, blood tests, and additional doses of medication will be required; remind patient to keep appointments.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.